Our latest clinical trial has been published showing selinexor has promising activity for the treatment of TP53 wild type KRAS mutant NSCLC.
utsouthwestern.edu/newsroom/artic…
doi.org/10.1158/1078-0…
utsouthwestern.edu/newsroom/artic…
doi.org/10.1158/1078-0…